# Integrative Analyses of Clinical Pharmacogenetic Data to Prevent Hospital Readmission in Real-World Health Systems > **NIH NIH R21** · ENDEAVOR HEALTH CLINICAL OPERATIONS · 2024 · $353,728 ## Abstract PROJECT SUMMARY/ABSTRACT Adverse drug reactions related to inadequately dosed or prescribed medications are a major cause of morbidity, mortality, and hospital readmissions in the United States. Pharmacogenetics research has identified genetic variants associated with response or toxicity for hundreds of drugs, and variant genotypes carried by some individuals may contribute disproportionately to medication-related hospital admissions. Yet the clinical utility of pharmacogenetics (PGx) when implemented in healthcare systems has not been widely established. In a resource-limited health system, it is not practical to genotype every patient, but if we can identify patients at higher risk of hospital admission based on medication prescribing events, we could be better able to discern which patients to approach with preemptive genotyping. We propose a cohort study within two learning healthcare systems with established PGx implementation programs – NorthShore University HealthSystem and The University of Chicago Center – in a pooled, ethnically diverse patient population of 5,726 patients – to evaluate the aggregate impact of pharmacogenetic drug interactions on readmissions and Emergency Department (ED) visits attributable to adverse drug reactions including inadequate drug response, over a two-year follow-up period. The overall goal of this project is to develop novel analytic methods to quantify the contribution of gene-x-drug interactions after hospital discharge to ED visits and readmissions, and to identify those individuals at greatest risk of these outcomes. Aim 1 is to estimate the rate of combined 90-day ED visits and readmissions attributable to inadequate drug response or toxicity and identify the clinical and demographic predictors of those admissions. Aim 2 is to identify 90-day ED visits and readmissions associated with adverse drug reactions among patients discharged on medications for which there is evidence of genetic variability for outcomes – focusing on medications with high-level evidence guidelines from the Clinical Pharmacogenomics Implementation Consortium and Food and Drug Administration labels prescribed and continued at hospital discharge on 90-day readmissions. Aim 3 will be to determine the contribution of specific genotypes to medication-related 90-day ED visits and readmissions visits among genotyped patients. This project is responsive to RFA HG-20-037 Advancing Genomic Medicine Research by facilitating analysis of clinical genomic data and will leverage the extensive experience of our team and dataset from two diverse, real-world healthcare systems across Chicagoland. Our multidisciplinary, collaborative team, aided by use of natural language processing, will screen electronic health records to extract de-identified patient data, curate, and apply innovative, integrated analytic methods to better identify patients who could benefit the most from preemptive PGx genotyping and pharmacovigilance to prevent ED visits and ... ## Key facts - **NIH application ID:** 10806325 - **Project number:** 1R21HG013413-01 - **Recipient organization:** ENDEAVOR HEALTH CLINICAL OPERATIONS - **Principal Investigator:** SEAN P. DAVID - **Activity code:** R21 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2024 - **Award amount:** $353,728 - **Award type:** 1 - **Project period:** 2024-02-15 → 2026-01-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10806325 ## Citation > US National Institutes of Health, RePORTER application 10806325, Integrative Analyses of Clinical Pharmacogenetic Data to Prevent Hospital Readmission in Real-World Health Systems (1R21HG013413-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10806325. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*